Ann: Chairman's Address to Shareholders, page-2

The continued support is wanting, as evidenced by our share price and lots of posts on HC.. outside of today’s AGM turning up some interstitial info, in regards to takeover prospects and opportunities, this thing has new studies, starting from scratch and other studies that they are finding hard to fill with human participants.

Agreed their results are increadible, they would be more increadible, if it were out in the community as a viable treatment for cancer, not just stage 4 participants with no hope left for survival but clinical trials..

The best way to get this out there is with$$$$ and the best way to get cavatak the $$ it needs is a takeover, at these share prices there must be interested parties who can then attract more participants to their trials, as their products ‘keytruda’ or ‘Yervoy’ are known to people who are looking for solutions. With trials full, cavatak should be fast tracked to market..

The best solution for everyone involved IMHO..